Transcript, protein, metabolite and cellular studies in skin fibroblasts demonstrate variable pathogenic impacts of NPC1 mutations.
Cholesterol transport
Lysosomal storage disease
Mutant protein
Niemann-pick type C
Proteostasis
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
05 04 2020
05 04 2020
Historique:
received:
27
11
2019
accepted:
17
03
2020
entrez:
7
4
2020
pubmed:
7
4
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Niemann-Pick type C (NP-C) is a rare neurovisceral genetic disorder caused by mutations in the NPC1 or the NPC2 gene. NPC1 is a multipass-transmembrane protein essential for egress of cholesterol from late endosomes/lysosomes. To evaluate impacts of NPC1 mutations, we examined fibroblast cultures from 26 NP-C1 patients with clinical phenotypes ranging from infantile to adult neurologic onset forms. The cells were tested with multiple assays including NPC1 mRNA expression levels and allele expression ratios, assessment of NPC1 promoter haplotypes, NPC1 protein levels, cellular cholesterol staining, localization of the mutant NPC1 proteins to lysosomes, and cholesterol/cholesteryl ester ratios. These results were correlated with phenotypes of the individual patients. Overall we identified 5 variant promoter haplotypes. Three of them showed reporter activity decreased down to 70% of the control sequence. None of the haplotypes were consistently associated with more severe clinical presentation of NP-C. Levels of transcripts carrying null NPC1 alleles were profoundly lower than levels of the missense variants. Low levels of the mutant NPC1 protein were identified in most samples. The protein localised to lysosomes in cultures expressing medium to normal NPC1 levels. Fibroblasts from patients with severe infantile phenotypes had higher cholesterol levels and higher cholesterol/cholesteryl ester ratios. On the contrary, cell lines from patients with juvenile and adolescent/adult phenotypes showed values comparable to controls. No single assay fully correlated with the disease severity. However, low residual levels of NPC1 protein and high cholesterol/cholesteryl ester ratios associated with severe disease. The results suggest not only low NPC1 expression due to non-sense mediated decay or low mutant protein stability, but also dysfunction of the stable mutant NPC1 as contributors to the intracellular lipid transport defect.
Sections du résumé
BACKGROUND
Niemann-Pick type C (NP-C) is a rare neurovisceral genetic disorder caused by mutations in the NPC1 or the NPC2 gene. NPC1 is a multipass-transmembrane protein essential for egress of cholesterol from late endosomes/lysosomes. To evaluate impacts of NPC1 mutations, we examined fibroblast cultures from 26 NP-C1 patients with clinical phenotypes ranging from infantile to adult neurologic onset forms. The cells were tested with multiple assays including NPC1 mRNA expression levels and allele expression ratios, assessment of NPC1 promoter haplotypes, NPC1 protein levels, cellular cholesterol staining, localization of the mutant NPC1 proteins to lysosomes, and cholesterol/cholesteryl ester ratios. These results were correlated with phenotypes of the individual patients.
RESULTS
Overall we identified 5 variant promoter haplotypes. Three of them showed reporter activity decreased down to 70% of the control sequence. None of the haplotypes were consistently associated with more severe clinical presentation of NP-C. Levels of transcripts carrying null NPC1 alleles were profoundly lower than levels of the missense variants. Low levels of the mutant NPC1 protein were identified in most samples. The protein localised to lysosomes in cultures expressing medium to normal NPC1 levels. Fibroblasts from patients with severe infantile phenotypes had higher cholesterol levels and higher cholesterol/cholesteryl ester ratios. On the contrary, cell lines from patients with juvenile and adolescent/adult phenotypes showed values comparable to controls.
CONCLUSION
No single assay fully correlated with the disease severity. However, low residual levels of NPC1 protein and high cholesterol/cholesteryl ester ratios associated with severe disease. The results suggest not only low NPC1 expression due to non-sense mediated decay or low mutant protein stability, but also dysfunction of the stable mutant NPC1 as contributors to the intracellular lipid transport defect.
Identifiants
pubmed: 32248828
doi: 10.1186/s13023-020-01360-5
pii: 10.1186/s13023-020-01360-5
pmc: PMC7132889
doi:
Substances chimiques
Carrier Proteins
0
Intracellular Signaling Peptides and Proteins
0
Membrane Glycoproteins
0
NPC1 protein, human
0
Niemann-Pick C1 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
85Références
Cell. 2016 Jun 2;165(6):1467-1478
pubmed: 27238017
J Biol Chem. 2008 Mar 28;283(13):8229-36
pubmed: 18216017
Biochim Biophys Acta. 2007 Jun;1771(6):663-76
pubmed: 17433772
Biochim Biophys Acta. 2006 Jan;1761(1):121-8
pubmed: 16458590
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
Hum Mutat. 2003 Oct;22(4):313-25
pubmed: 12955717
Cell. 2015 Apr 9;161(2):291-306
pubmed: 25860611
J Med Genet. 2000 Sep;37(9):707-12
pubmed: 11182931
Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18932-6
pubmed: 22065762
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Biol Chem. 1986 Dec 15;261(35):16769-74
pubmed: 3782141
Acta Histochem. 1974;50(1):110-5
pubmed: 4140671
BMC Neurol. 2015 Dec 15;15:257
pubmed: 26666848
FEBS J. 2014 Oct;281(19):4450-66
pubmed: 25131710
Am J Hum Genet. 2001 Jun;68(6):1373-85
pubmed: 11333381
Sci Transl Med. 2016 Sep 7;8(355):355ra118
pubmed: 27605553
Genet Med. 2016 Jan;18(1):41-8
pubmed: 25764212
Science. 2000 Sep 22;289(5487):2117-20
pubmed: 11000112
Science. 2009 Jul 24;325(5939):473-7
pubmed: 19556463
J Neurosci. 2009 May 20;29(20):6394-405
pubmed: 19458211
Orphanet J Rare Dis. 2018 Apr 6;13(1):50
pubmed: 29625568
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5886-91
pubmed: 15071184
Biochem Biophys Res Commun. 1999 Aug 2;261(2):493-8
pubmed: 10425213
Orphanet J Rare Dis. 2010 Jun 03;5:16
pubmed: 20525256
Cell. 1999 Feb 5;96(3):307-10
pubmed: 10025395
J Child Neurol. 2010 Mar;25(3):300-5
pubmed: 19822772
J Lipid Res. 2010 Feb;51(2):406-15
pubmed: 19744920
Methods Cell Biol. 2015;126:357-75
pubmed: 25665455
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19316-21
pubmed: 19884502
Mol Endocrinol. 2003 Apr;17(4):704-15
pubmed: 12554781
FASEB J. 1987 Jul;1(1):40-5
pubmed: 3609608
J Biol Chem. 2005 Mar 25;280(12):11731-9
pubmed: 15644330
J Lipid Res. 2008 May;49(5):1090-102
pubmed: 18272927
J Lipid Res. 2010 May;51(5):1023-34
pubmed: 19965586
Mol Genet Metab. 2017 Mar;120(3):180-189
pubmed: 27993458
J Inherit Metab Dis. 2006 Aug;29(4):591
pubmed: 16802107
Biochim Biophys Acta. 1991 Jun 5;1096(4):328-37
pubmed: 2065104
Clin Genet. 2005 Sep;68(3):245-54
pubmed: 16098014
J Lipid Res. 2008 May;49(5):1024-33
pubmed: 18272928
Am J Hum Genet. 2001 Jun;68(6):1361-72
pubmed: 11349231
Chem Biol. 2013 Mar 21;20(3):391-402
pubmed: 23521797
Sci Rep. 2019 Mar 28;9(1):5292
pubmed: 30923329
J Lipid Res. 2012 Dec;53(12):2632-42
pubmed: 22962690
Mol Genet Metab Rep. 2015 Mar 06;3:18-20
pubmed: 26937389
Science. 2000 Dec 22;290(5500):2298-301
pubmed: 11125141
Orphanet J Rare Dis. 2018 Oct 1;13(1):175
pubmed: 30285904
Brain Res. 2016 Oct 15;1649(Pt B):181-188
pubmed: 27026653
JIMD Rep. 2017;36:41-48
pubmed: 28105569
Am J Hum Genet. 1999 Nov;65(5):1321-9
pubmed: 10521297
Exp Cell Res. 2000 Aug 25;259(1):247-56
pubmed: 10942596
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10079-84
pubmed: 27551080
Hum Genet. 2001 Jul;109(1):24-32
pubmed: 11479732
Orphanet J Rare Dis. 2014 Sep 19;9:140
pubmed: 25236789
Mol Genet Metab. 2016 Aug;118(4):244-54
pubmed: 27339554
J Lipid Res. 2011 Apr;52(4):813-25
pubmed: 21245028
Science. 1997 Jul 11;277(5323):228-31
pubmed: 9211849
Sci Transl Med. 2015 Feb 25;7(276):276ra26
pubmed: 25717099
Anal Biochem. 1987 Apr;162(1):156-9
pubmed: 2440339